Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Prescribing

Gabapentin, pregabalin and oxycodone prescriptions in England increased each year between 2013 and 2018

Prescriptions for pregabalin increased by 1.8 times between 2013/2014, but gabapentin was the most prescribed of the three medicines, reaching 6.7 million prescriptions in 2017/2018.

Gabapentin

Source: Shutterstock.com

The researchers said the increase in gabapentin (pictured) and pregabalin prescribing could be a result of greater scrutiny of the prescribing of tramadol and other opioid-based analgesics

Prescriptions for gabapentin, pregabalin and oxycodone increased year on year between 2013 and 2018 across primary care in England, study results published in BJGP Open show

This increase could be driving harm in the form of drug-related mortality and morbidity, the researchers said.

The study was a retrospective secondary analysis of primary care prescribing data aggregated by NHS Digital each month for all general practices in England from April 2013 to March 2018.

The researchers found that the largest increase in prescribing was seen in pregabalin, for which prescriptions increased 1.8 times between 2013/2014 and 2017/2018. However, gabapentin was the most prescribed of the three medicines, at 6.7 million prescriptions in 2017/2018.

The researchers also discovered a positive association between prescribing and levels of deprivation. In England, GP practices located within the most deprived quintiles issued 313%, 238% and 254% more prescriptions per head per GP practice of gabapentin, pregabalin and oxycodone, respectively, than those in the least deprived quintile.

The researchers said the increase in gabapentin and pregabalin prescribing could be a result of greater scrutiny of the prescribing of tramadol and other opioid-based analgesics, following the reclassification of tramadol in 2014 as a Schedule 3 controlled drug.

“More research is needed to understand the large variation in prescribing between general practices, and to develop and implement interventions to reduce unwarranted variation and increase the appropriateness of prescribing of these drugs,” they concluded. 

From 1 April 2019, pregabalin and gabapentin were reclassified as Class C controlled substances in the UK over concerns about their misuse. 

It was expected that the change, announced in October 2018, would prompt a decline in the use of these medicines by making prescribing, dispensing and collecting them more difficult. Oxycodone is a Class A medication. 

Emma Davies, an advanced pharmacy practitioner in pain management at Abertawe Bro Morgannwy University Health Board in Wales, described the findings as “extremely significant”.

“The rises in prescribing and associated increase in associated deaths and escalating misuse are what led to the rescheduling decision,” she said.

“More interesting, perhaps, is whether the rescheduling will impact on the prescribing trends in future. It isn’t at all clear that rescheduling tramadol led to reductions in its use.”

However Davies pointed out that England had seen increases in all “strong” opioids and that it was “wrong” to focus on single drugs. 

“We saw that with tramadol — it potentially pushes prescribers into just prescribing an alternative rather than addressing the real issue, which is ‘why do we prescribe these medicines when they don’t work and cause harm?’.” 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207079

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.